Preclinical News and Research

RSS

Scientists develop first dual-action drug against melanoma skin cancer cells

Scientists are reporting development and successful lab tests on the first potential drug to pack a lethal one-two punch against melanoma skin cancer cells. Hit number one destroys cells in the main tumor, and the second hit blocks the spread of the cancer to other sites in the body, according to their report in the journal ACS Chemical Biology.

6 Jun 2013

MJFF commits up to $10 million to find cure for Parkinson's disease

The Michael J. Fox Foundation for Parkinson's Research has committed up to $10 million to its next funding round for the Edmond J. Safra Core Programs for PD Research to prioritize research toward transformative treatments and a cure for Parkinson's disease.

5 Jun 2013

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.

4 Jun 2013

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology in Chicago, IL.

4 Jun 2013

Study: Mutations in gene NTRK1 cause a subset of lung cancers

To the list of oncogenic drivers of lung cancer that includes ALK, EGFR, ROS1 and RET, results of a University of Colorado Cancer Center study presented at ASCO 2013 show that mutations in the gene NTRK1 cause a subset of lung cancers.

4 Jun 2013

Study provides important details for recently identified target in lung adenocarcinoma

In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: rearrangement of the gene RET.

4 Jun 2013

Arcturus Therapeutics closes $1.3 M in seed funding round

Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of disease, today announced it has raised $1.3 million in a seed funding round led by multiple high net-worth private investors from the United States and Canada.

3 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

3 Jun 2013

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacological therapy that shows promise for treating both solid-tumor cancers and hematologic malignancies.

1 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.

30 May 2013

Gene therapy techniques show promise in promoting growth of skin, bone and other tissues

Experimental genetic techniques may one day provide plastic and reconstructive surgeons with an invaluable tool-the ability to promote growth of the patient's own tissues for reconstructive surgery.

30 May 2013

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of a Phase 2b clinical study of TC-5214 as a treatment for overactive bladder.

29 May 2013

Resolvins may help protect against cognitive decline after surgery

Resolvins are molecules naturally produced by the body from omega-3 fatty acids - a process that can be jumpstarted by common aspirin. In a new study, published in The FASEB Journal, researchers at Karolinska Institutet describe how resolvins could protect against the cognitive impairment that often affects recovery of surgical and critically ill patients.

28 May 2013

Frutarom reports increased demand for natural ingredient targeting urinary incontinence in adults

Frutarom Health, Switzerland, reports increased demand for Go-Less, its natural ingredient targeting urinary incontinence in adults.

28 May 2013

Liposomal anthracycline-based chemotherapy effective for children with leukemia: Study

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology.

24 May 2013

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its investigational, once daily, oral therapy for the treatment of HCV infection.

24 May 2013

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

23 May 2013

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.

23 May 2013

Preclinical News and Research

Scientists develop first dual-action drug against melanoma skin cancer cells

MJFF commits up to $10 million to find cure for Parkinson's disease

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

Study: Mutations in gene NTRK1 cause a subset of lung cancers

Study provides important details for recently identified target in lung adenocarcinoma

Arcturus Therapeutics closes $1.3 M in seed funding round

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

Gene therapy techniques show promise in promoting growth of skin, bone and other tissues

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Resolvins may help protect against cognitive decline after surgery

Frutarom reports increased demand for natural ingredient targeting urinary incontinence in adults

Liposomal anthracycline-based chemotherapy effective for children with leukemia: Study

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics